Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers

This open-label, radiolabeled, single 100-mg dose study in approximately 6 healthy male
volunteers has been designed to further the understanding of human metabolism of lorlatinib.
A prior radiolabel study using [14C]lorlatinib (study B7461004) identified an unexpected
major metabolite in plasma; a benzoic acid metabolite (M8, PF-06895751) resulting from
cleavage of the amide and aromatic ether bonds of lorlatinib, accounting for 21.0% of the
circulating radioactivity or ~ 47.3% plasma M8 to lorlatinib AUC percent ratio. However, due
to the position of the 14C radiolabel on the carbonyl carbon, the metabolic fate of the
larger fragment of lorlatinib resulting from this cleavage, the pyrido-pyrazole substructure,
could not be determined. In this current study, the radiolabel will be on the pyrazole ring
allowing for monitoring the metabolic fate of the pyrido-pyrazole part of the lorlatinib
molecule cleaved during the formation of the M8 metabolite. Since the M8 metabolite will not
be radiolabeled, its concentrations in plasma will be determined using a validated liquid
chromatography tandem mass spectrometric (LC/MS/MS) assay.

The sample size of approximately 6 was selected to ensure at least 4 fully evaluable subjects
with completed collections of plasma, urine, and fecal samples. This is a standard sample
size used for mass-balance/ADME studies which include assessment of metabolic profiling, and
is not based on empirical data or hypothesis testing criteria.

Metabolic profiling of radiolabeled components will be performed on pooled plasma samples as
well as on cumulative urine and feces excreted until Day 14 postdose or until one of the
early release criteria is met. The early release criteria are: 1) recovery in excreta of at
least 90% of administered radioactivity, or 2) less than 1% of administered radioactivity
being recovered in excreta from two consecutive days (ie, total for urine + feces should be
<1% on 2 consecutive days). Plasma concentrations of both lorlatinib and its unlabeled M8
metabolite will be analyzed using validated assays. Information from this study will
complement the metabolic profiling results from study B7461004, will help guide in the
assessment of potential drug-drug interactions (DDIs) and the need for other DDI studies with
lorlatinib, and will aid in the understanding of the possible causes for the unexpected
findings from a DDI study where a single 100 mg dose of lorlatinib was co-administered with
600 mg rifampin QD (study B7461011).

Banked biospecimens will be collected for the purpose of conducting research; specific uses
are described in the Banked Biospecimens section. Comparing the deoxyribonucleic acid (DNA),
ribonucleic acid (RNA), protein, and metabolite variation patterns of subjects who respond
well and those who respond poorly to treatment may help to better define the most appropriate
group of subjects in which to target a given treatment. Collecting biospecimens for
exploratory pharmacogenomic/genomic/biomarker analyses and retaining them in the Biospecimen
Banking System (BBS) make it possible to better understand the investigational product's
mechanism of action and to seek explanations for differences in, for example, exposure,
tolerability, safety, and/or efficacy not anticipated prior to the beginning of the study.

Inclusion Criteria:

1. Healthy (no clinically relevant abnormalities) males, 18 to 55 years at the time of
screening.

2. BMI of 17.5-30.5 kg/m2; and a total body weight >50 kg (110 lb).

3. Evidence of a personally signed and dated informed consent document indicating that
the subject has been informed of all pertinent aspects of the study.

4. Willing and able to comply with all scheduled visits, treatment plan, laboratory
tests, and other study procedures.

Exclusion Criteria:

1. Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, CV, hepatic, psychiatric, neurological, or allergic
disease (including drug allergies, but excluding seasonal allergies).

2. Any condition possibly affecting drug absorption (eg, gastrectomy).

3. A positive urine drug test.

4. History of regular alcohol consumption exceeding 14 drinks/week within 6 months before
screening.

5. Treatment with an investigational drug within 30 days (or as determined by the local
requirement) or 5 half-lives preceding the dose of investigational product (whichever
is longer).

6. Screening BP ≥ 140 mm Hg (systolic) or 90 mm Hg (diastolic) following at least 5
minutes of rest. If systolic or diastolic BP is higher at screening, repeat 2 times
and use average of 3 BP values.

7. Screening supine 12 lead ECG QTc interval >450 msec or QRS interval >120 msec, or PR
interval > 180 msec. If QTc or QRS exceed, ECG should be repeated 2 more times and the
average of the 3 QTc or QRS should be used.

8. Subjects with ANY of the following abnormalities in clinical laboratory tests at
screening (and confirmed with single repeat): AST or ALT level > 1.0 × ULN; Total
bilirubin level > 1.5 × ULN. If history of Gilbert's syndrome, subject would be
eligible provided the direct bilirubin level is ≤ ULN.

9. Use of prescription or nonprescription drugs and dietary supplements within 7 days or
5 half-lives (whichever is longer) prior to study drug dose. Acetaminophen may be used
at dosed up to 1 g/day. Limited use of nonRx medications may be permitted following
approval by the sponsor. Herbal supplements and hormone replacement therapy must have
been discontinued at least 28 days prior to study drug dose.

10. Blood donation (excluding plasma) of ~ 1 pint (500 mL) or more within 60 days prior to
dosing.

11. History of HIV, hepatitis B, or hepatitis C; positive testing for HIV, HepBsAg,
HepBcAb, or HCVAb.

12. Unwilling or unable to comply with the criteria in the Lifestyle Requirements section.

13. Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members supervised by the investigator, or subjects
who are Pfizer employees, including their family members, directly involved in the
conduct of the study.

14. Other acute or chronic medical or psychiatric condition including recent (within the
past year) or active suicidal ideation or behavior or laboratory abnormality that may
increase the risk associated with study participation or investigational product
administration or may interfere with the interpretation of study results.

15. History of irregular bowel movements eg, regular episodes of diarrhea or constipation,
irritable bowel syndrome or lactose intolerance.

16. Enrolled in a previous radionucleotide study or who have received radiotherapy within
12 months prior to screening or such that total radioactivity would exceed acceptable
dosimetry (ie, occupational exposure of 5 rem per year).

17. Subjects whose occupation requires exposure to radiation or monitoring of radiation
exposure.

18. Subjects who have used tobacco within 90 days prior to dosing.

19. Male subjects with partners currently pregnant; male subjects able to father children
who are unwilling or unable to use 2 highly effective methods of contraception as
outlined in this protocol for the duration of the study and for at least 90 days after
the last dose of investigational product.